Reiterated Audentes Therapeutics (BOLD) Rating.

Mizuho Securities’s Research professionals have $45 PT which indicates upside potential of 36.70 % on Audentes Therapeutics (BOLD). a research note of the firm was revealed on Thursday, 28 February.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Coverage

In total 10 analysts cover Audentes Therapeutics (BOLD). “Buy” rating has 8, “Sell” are 1, while 1 are “Hold”. 80% are bullish. 13 are the (BOLD)’s analyst reports since September 7, 2018 according to StockzIntelligence Inc. In Wednesday, February 27 report Piper Jaffray maintained the stock with “Buy” rating. On Sunday, February 24 Chardan Capital Markets upgraded Audentes Therapeutics, Inc. (NASDAQ:BOLD) to “Buy” rating. On Friday, January 11 the firm has “Buy” rating by Guggenheim given. On Thursday, February 28 the company was maintained by Mizuho. On Wednesday, November 7 William Blair downgraded the shares of BOLD in report to “Market Perform” rating. On Monday, December 10 the company was maintained by Citigroup. On Thursday, February 28 H.C. Wainwright maintained Audentes Therapeutics, Inc. (NASDAQ:BOLD) with “Buy” rating. On Friday, October 12 the firm has “Buy” rating given by H.C. Wainwright. On Monday, November 26 the stock of Audentes Therapeutics, Inc. (NASDAQ:BOLD) earned “Buy” rating by J.P. Morgan. The company rating was maintained by Wedbush on Monday, October 8.

Ticker’s shares touched $32.92 during the last trading session after 7.51% change.Audentes Therapeutics, Inc. has volume of 306,471 shares. Since March 1, 2018 BOLD has declined 19.28% and is downtrending. BOLD underperformed by 19.28% the S&P 500.

Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s quarterly earnings will be published on March, 14., RTT reports. Last year’s EPS was $-0.82, while now analysts expect change of 12.20 % down from current $-0.92 EPS. Wall Street predicts -5.15 % EPS growth as of March, 14.

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects.The firm is valued at $1.41 billion. The firm is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy ; AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.Currently it has negative earnings. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar.

For more Audentes Therapeutics, Inc. (NASDAQ:BOLD) news posted briefly go to: Prnewswire.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Audentes Therapeutics Recognizes Rare Disease Day by Launching “Be Bold for Courageous Patients” Program to Support Patients Living with Rare Diseases – PRNewswire” posted on February 28, 2019, “Does a Big Earnings Miss Mean Trouble at Harley Davidson? – Nasdaq” on January 30, 2019, “First Week of BOLD March 15th Options Trading – Nasdaq” with a publish date: February 08, 2019, “Reed’s Inc. Announces Closing of Underwritten Public Offering of Common Stock – Nasdaq” and the last “Sysco’s Cutting Edge Solutions Announces Additional Product Offerings – Nasdaq” with publication date: February 18, 2019.